Association between growth hormone therapy and mortality, cancer and cardiovascular risk: Systematic review and meta-analysis

Annalisa Deodati, Barbara Baldini Ferroli, Stefano Cianfarani

Research output: Contribution to journalArticle

Abstract

Objective: The potential involvement of growth hormone therapy in tumor promotion and progression has been of concern for several decades. Our aim was to assess systematically the association between growth hormone therapy and all-cause, cancer and cardiovascular mortality, cancer morbidity and risk of second neoplasm mainly in patients treated during childhood and adolescence. Design: A systematic review of all articles published until September 2013 was carried out. The primary efficacy outcome measures were the all-cause, cancer and cardiovascular standardized mortality ratios (SMR). The secondary efficacy outcome measures were the standardized incidence ratio (SIR) for cancer and the relative risk (RR) for second neoplasms. The global effect size was calculated by pooling the data. When the effect size was significant in a fixed model we repeated the analyses using a random model. Results: The overall all-cause SMR was 1.19 (95% CI 1.08-1.32, p.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalGrowth Hormone and IGF Research
Volume24
Issue number4
DOIs
Publication statusPublished - 2014

    Fingerprint

Keywords

  • Growth hormone
  • Growth hormone therapy
  • IGF-I
  • Metaanalysis

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this